March 7, 2024 06:48 AM ESTUpdated 05:38 PM

GSK declares second PhIII win for Blenrep combo in bid to revive drug

Amber Tong

Blenrep, GSK’s BCMA-targeting antibody-drug conjugate, has once again beat the standard of care when given as part of a combination to patients with relapsed/refractory multiple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK declares second PhIII win for Blenrep combo in bid to revive drug

Amber Tong

Sign up to read this article for free.

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Neurogene patient had life-threatening side effect in Rett syndrome study

Novartis strikes radiopharma deal with Ratio worth up to $745M

Are programs with compounded GLP-1s safe for your population?

GSK de­clares sec­ond PhI­II win for Blenrep com­bo in bid to re­vive drug

Amber Tong

Sign up to read this article for free.

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

GSK declares second PhIII win for Blenrep combo in bid to revive drug

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Neurogene patient had life-threatening side effect in Rett syndrome study

Novartis strikes radiopharma deal with Ratio worth up to $745M

Are programs with compounded GLP-1s safe for your population?